Steve Lam has been appointed senior vice president of Patheon’s biologics business, reporting to Lukas Utiger, president of the company’s Drug Substance Services (DSS) segment.   

Mr. Lam most recently served as vice president of operations for Amgen, where he led a company-wide initiative driving quality management processes and operational excellence. He has more than than 25 years of leadership experience in biopharmaceutical operations with a focus on manufacturing and commercializing. He has specific expertise in protein manufacturing, cGMP compliance, quality systems and technology transfer.

“Our biologics business is an area with tremendous growth potential for Patheon,” said Mr. Utiger. “With Steve’s experience and his broad client perspective, he will energize our efforts and support our biopharmaceutical clients who are looking for a knowledgeable partner with scale and expertise to meet their needs. He will help us to continue to pursue strategies that capitalize on this expanding area of our business.”